XML 219 R162.htm IDEA: XBRL DOCUMENT v3.25.0.1
Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]      
Beginning balance [1] € 709 € 779 € 714
New transactions [1] 0 0 156
Payments made [1] (71) (167) (136)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) [1],[2] 109 114 5
Other movements [1] (139) 0 0
Currency translation differences [1] 33 (17) 40
Ending balance [1] 641 709 779
Non-current liabilities related to business combinations and to non-controlling interests 569 501 674
Current liabilities related to business combinations and to non-controlling interests 72 208 105
Bayer contingent purchase consideration arising from the acquisition of Genzyme      
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]      
Beginning balance 0 26 59
New transactions 0 0 0
Payments made 0 (21) (29)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) [2] 0 (5) (9)
Other movements 0 0 0
Currency translation differences 0 0 5
Ending balance 0 0 26
MSD contingent consideration (European vaccines business)      
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]      
Beginning balance 127 204 269
New transactions 0 0 0
Payments made (70) (77) (79)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) [2] 16 0 14
Other movements 0 0 0
Currency translation differences (1) 0 0
Ending balance 72 127 204
Shire contingent consideration arising from the acquisition of Translate Bio      
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]      
Beginning balance 441 380 354
New transactions 0 0 0
Payments made 0 0 0
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) [2] 94 74 2
Other movements 0 0 0
Currency translation differences 33 (13) 24
Ending balance 568 441 380
Amunix [Member]      
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]      
Beginning balance 137 165 0
New transactions 0 0 156
Payments made 0 (69) 0
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) [2] 0 45 (2)
Other movements (137) 0 0
Currency translation differences 0 (4) 11
Ending balance 0 137 165
Other      
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]      
Beginning balance 4 4 32
New transactions 0 0 0
Payments made (1) 0 (28)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) [2] 1 0 0
Other movements (3) 0 0
Currency translation differences 0 0 0
Ending balance € 1 € 4 € 4
[1] (a)Portion due after more than one year: €569 million as of December 31, 2024 (€501 million as of December 31, 2023 and €674 million as of December 31,
2022); portion due within less than one year: €72 million as of December 31, 2024 (€208 million as of December 31, 2023 and €105 million as
of December 31, 2022).
[2] (b)Amounts reported within the income statement line item Fair value remeasurement of contingent consideration, and mainly comprising unrealized gains and losses